Diabetes mellitus and cardiovascular disease in women

Archives of Internal Medicine

Volumn 158, Issue 6, 1998, Pages 617-621

  Sowers, James R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; PROGESTERONE; PROTECTIVE AGENT; SEX HORMONE;

ARTICLE; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIUM INJURY; FEMALE; HORMONE ACTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; OVARY FUNCTION; POSTMENOPAUSE; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOCYTE ANOMALY;

BLOOD COAGULATION; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; RISK FACTORS; SEX FACTORS;

EID: 0032559777     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.6.617     Document Type: Article

References (75)

1. World Health Statistics Annual Report. Vital Statistics and Cause of Death. Geneva, Switzerland: World Health Organization; 1990.
2. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
3. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;1:383-390.
4. Hanes DS, Weir MR, Sowers JR. Gender considerations in hypertension pathophysiology and treatment. Am J Med. 1996;101(suppl 3A):10S-21S.
5. Anastos K, Charney P, Charon RA, et al. Hypertension in women: what is really known? The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine. Ann Intern Med. 1991;115:287-293.
6. Maynard C, Litwin PE, Martin JS, et al. Gender differences in the treatment and outcome of acute myocardial infarction: results from the Myocardial Infarction Triage and Intervention Registry. Arch Intern Med. 1992;152:972-976.
7. American Heart Association. Heart and Stroke Facts. Dallas, Tex: American Heart Association; 1992.
8. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153:2209-2216.
9. The National High Blood Pressure Education Working Program. National High Blood Pressure Education Program Working Group Report on Hypertension in Diabetes. Hypertension. 1994;23:145-158.
10. Sowers JR, Epstein M. Diabetes mellitus and hypertension: an update. Hypertension. 1995;26:869-879.
11. Albert C. Sex differences in cardiac arrest survivors. Circulation. 1996;93:1170-1176.
12. Colburn P, Buonassisi V. Estrogen binding sites in endothelial cell cultures. Science. 1978;210:817-819.
13. Horwitz KB, Horwitz LD. Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest. 1982;69:750-758.
14. 2+ currents in vascular smooth muscle. Am J Physiol. 1994;193: C975-C980.
15. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhare G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A. 1992;89:11259-11263.
16. Conrad KP, Jaffe GM, Kruszyna R, et al. Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J. 1993;7:566-571.
17. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A. 1994;91:5212-5216.
18. Hayashi T, Yamada K, Esaki T, et al. Estrogen increases endothelial nitric oxide by a receptor mediated system. Biochem Biophys Res Commun. 1995;214:847-855.
19. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990;81:1680-1687.
20. Walsh BW, Schiff I, Rosner B, Grienberg L, Ravnikar V, Sacks F. Effects of post-menopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
21. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol. 1992;69:176-178.
22. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936-941.
23. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med. 1995;25:370-377.
24. Sullivan JM, Vander Zwaag R, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med. 1988;108:358-363.
25. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
26. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Post-menopausal Estrogen/Progestin Interventions Trial. JAMA. 1995;273:199-208.
27. Simpson LL, Zhang F, Standley PR, Ram JL, Weir MR, Sowers JR. Role of calcium in vascular smooth muscle proliferation: antiproliferative effects of verapamil enantiomers - independence from calcium channel blockade. J Vasc Med Biol. 1994;5:46-53.
28. Orimo A, Inoue S, Ikegami A, et al. Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Commun. 1993;195:730-736.
29. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation. 1994;89:1501-1510.
30. Knauthe R, Diel P, Hagele-Haratung C, Engelhaapt A, Fritzemeir K. Sexual dimorphoism of steroid hormone receptor messenger ribonucleic acid expression and hormonal regulation in rat vascular tissue. Endocrinology. 1996;137: 3220-3227.
31. Campisi D, Cutolo M, Carruba G, et al. Evidence for soluble and nuclear site I binding of estradiol in human aorta. Atherosclerosis. 1993;103:267-277.
32. Lin AL, Gonzalez R, Carey KD, Shain SA. Gender and baboon aortic steroid hormone receptors. Atherosclerosis. 1987;7:248-255.
33. Walsh MF, Dominguez LJ, Sowers JR. Metabolic abnormalities in cardiac ischemia. Cardiol Clin. 1995;13:529-538.
34. Welch CC, Proudift WL, Sheldon WC. Coronary arteriographic findings in 1,000 women under age 50. Am J Cardiol. 1975;35:211-215.
35. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants of the Framingham Heart Study. Circulation. 1983;67:968-976.
36. Lerner DJ, Kannel WB. Patterns of coronary disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986; 111:383-390.
37. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow-up of participants in the population study of women of Gothenburg, Sweden. BMJ. 1984;289:1257-1261.
38. Gillum RF. The association of body fat distribution with hypertension, hypertensive heart disease, coronary heart disease, diabetes and cardiovascular risk factors in men and women aged 18-79 years. J Chronic Dis. 1987;40:421-428.
39. Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program. JAMA. 1991;265:3255-3264.
40. Lewis CE, Grandits GA, Flack J, McDonald R, Elmer PJ. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Arch Intern Med. 1996;156:377-385.
41. Davis BR, Cutler JA, Gordon DJ, et al, for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
42. Walsh JME, Grady D. The treatment of hyperlipidemia in women. JAMA. 1995; 274:1152-1158.
43. Barrett-Connor E, Wingard DL. Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol. 1983; 118:489-496.
44. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: sixteen-year follow-up study. Diabetes Care. 1990;13:631-654.
45. Barrett-Connor E, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA. 1991;265:627-631.
46. USRDS 1995 Annual Data Report: incidence and causes of treated ESRD. Am J Kidney Dis. 1995;26(suppl):S39-S50.
47. Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women: the Framingham Study. Arch Intern Med. 1996;156:505-509.
48. Darvi G, Catalons I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322:1769-1774.
49. Standley PR, Ali S, Bapna C. Sowers JR. Increased platelet cytosolic calcium responses to low density lipoprotein in type II diabetes with and without hypertension. Am J Hypertens. 1993;6:938-943.
50. Carmassi F, Morale M, Puccetti R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res. 1992;67:643-654.
51. Betteridge DJ. Diabetic dyslipidemia. Am J Med. 1994;96(suppl 6A):25S-31S.
52. Williams SB, Cusco JA, Roddy MA, Johnstone MA, Creager MA. Impaired nitric oxide-mediated vasodilation in non-insulin-dependent diabetes. Circulation. 1994; 90:I-50-I-53.
53. Goodfellow J, Ramsey MW, Luddington LA, et al. Flow-related endothelial function is impaired in non-insulin dependent diabetes. Circulation. 1994;90: I-513.
54. Clarkson P, Celermajer DS, Yue DK, et al. Endothelial dysfunction in insulin-dependent diabetes mellitus relates to the duration of disease and LDL-cholesterol level. Circulation. 1995;92:I-1107.
55. Guigliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic complications. Diabetes Care. 1996;19:257-267.
56. Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension. 1997;29:691-699.
57. Donahue RP, Barrett-Connor E, Orchard TJ, Gutai JP. Endogenous insulin and sex hormones in atherosclerosis and coronary heart disease. Arteriosclerosis. 1988;8:544-548.
58. Capron L, Jarnet J, Kusandjian S, Honsait E. Growth promoting effects of diabetes and insulin on arteries. Diabetes. 1986;35:973-978.
59. Oppenheimer MJ, Sundquist K, Bierman EL. Down-regulation of high-density lipoprotein receptor in human fibroblasts by insulin and IGF-1. Diabetes. 1989; 38:117-122.
60. Hamet P, Skuherska R, Pang SC, Tremblay J. Abnormalities of platelet function in hypertension and diabetes. Hypertension. 1985;7(suppl II):II-135-II-142.
61. Nadler JL, Malayan S, Luong H, Shaw S, Natarajan R, Rude B. Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. Diabetes Care. 1992;15:835-841.
62. Jacobs DB, Sowers JR, Hmeidan A, Niyogi T, Simpson L, Standley PR. Effects of weight reduction on cellular cation metabolism and vascular resistance. Hypertension. 1993;21:308-314.
63. Levy J, Gavin JR III, Sowers JR. Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med. 1994;96:260-270.
64. Ford I, Singh TP, Kitchen S, Makris M, Ward JD, Preston FD. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabetes Med. 1991;8:322-329.
65. Carmassi F, Morale M, Puccetti R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Rev. 1992;67:643-654.
66. Vukovich TC, Proidl S, Knöbl P, Teufelsbauer H, Schnack O, Schernthaner G. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. Thromb Haemost. 1992;6:253-256.
67. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273-278.
68. 1 and fasting serum glucose in young diabetic women. Diabetes Care. 1980;3:655-658.
69. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BW, Raskin P. Lipoprotein (a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med. 1992;117:42-47.
70. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A. 1993;90: 6434-6438.
71. Lyons TJ, Lopes-Virella MF, Baystle JW. Glycation, oxidation, and glyoxidation in the pathogenesis of atherosclerosis in diabetes. Mod Med. 1993;61(suppl 2): 4-8.
72. Hsueh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension. 1992;20:253-263.
73. Tesfamariam B, Brown ML, Conen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest. 1991;87:1643-1648.
74. Cagliero E, Roth T, Roy S, Lorenzi M. Characteristics and mechanisms of high-glucose-induced overexpression of basement membrane components in cultured human endothelial cells. Diabetes. 1991;40:102-110.
75. Creager MA, Cooke JP, Mendelsohn M, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228-234.